Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 9 of 15
May 22, 2026The dental and vision benefits market is undergoing significant transformation driven by multiple converging trends. Stakeholders in this market are adapting to new contracting methods, technological advancements, and evolving care models that emphasize value and patient outcomes.
May 22, 2026Recordati has been approached by CVC Capital Partners and Groupe Bruxelles Lambert with a proposal to take the company private. The offer includes a 13% premium and aims to grant Recordati long-term strategic flexibility and capital stability amidst a competitive industry landscape.
May 21, 2026The timely award of Medicaid funds to Florida hospitals represents a critical development with substantial implications for healthcare infrastructure and funding. This blog post explores the background, context, and potential impacts of this investment on Florida's healthcare landscape.
May 21, 2026GHO Capital and CBC Group plan to merge, pooling their assets totaling approximately $21 billion. This merger is expected to significantly reshape the healthcare investment landscape by creating a formidable new player with extensive global reach and investment capabilities.
May 15, 2026Hospital-acquired infections remain a significant challenge in clinical settings, leading to increased morbidity, mortality, and healthcare costs. Shyld AI's innovative autonomous UV disinfection technology represents a promising approach to improving infection control while easing operational burdens on hospital staff.
May 10, 2026The immunology-focused biotech company Windward Bio is advancing its pipeline of long-acting antibodies aimed at respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). These therapies promise extended dosing intervals compared to existing biologics, potentially improving patient adherence and outcomes.
May 9, 2026The significant capital infusion allows Odyssey to evaluate its small molecule treatment in combination with Takeda’s Entyvio and as a standalone therapy, reflecting the company’s strategic focus on advancing innovative immunology drugs to meet unmet patient needs.
May 8, 2026The healthcare industry is facing significant financial challenges as bankruptcy filings increase, marking a critical turning point for outpatient and senior care sectors. This post examines the underlying causes, recent market trends including hospital merger and acquisition activity, and potential paths forward for stakeholders.
May 7, 2026As regulatory pressures intensify, private equity firms are adapting their healthcare investment approaches. This article analyzes the evolving strategies aimed at improving patient outcomes and operational efficiency.
May 6, 2026The startup gained significant investment from a diverse group of venture funds and insurers, highlighting the growing interest in health technologies that facilitate aging in place. These partnerships will promote broader adoption and integration of Rosarium’s solutions into healthcare systems.
May 4, 2026As the biopharmaceutical sector navigates a changing public market landscape, companies like Odyssey and Seaport Therapeutics are at the forefront of a renewed IPO momentum. Analysts remain cautiously optimistic about the implications of these moves for industry investors.
May 3, 2026In April 2026, the biotechnology sector experienced a major capital boost as four biotech companies joined public markets through upsized IPOs, raising a record $1.5 billion. Companies such as Hemab Therapeutics and Seaport Therapeutics led this wave, signaling renewed optimism in biotech innovation and investment.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.